Pretreatment with relaxin does not restore no-mediated modulation of calcium signal in coronary endothelial cells isolated from spontaneously hypertensive rats by Nistri, Silvia et al.
22 October 2021
Pretreatment with relaxin does not restore no-mediated modulation of calcium signal in coronary endothelial cells
isolated from spontaneously hypertensive rats / Nistri, S; Di Cesare Mannelli, L; Ghelardini, C; Zanardelli, M; Bani, D;
Failli, P.. - In: MOLECULES. - ISSN 1420-3049. - ELETTRONICO. - 20(2015), pp. 9524-9535.
[10.3390/molecules20069524]
Original Citation:
Pretreatment with relaxin does not restore no-mediated modulation of calcium





(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1025982 since: 2017-06-22T11:37:12Z
Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:
FLORE




Pretreatment with relaxin does not restore NO-mediated modulation of calcium signal in 


















Clinical & Experimental Medicine, Research Unit of Histology & Embryology 
and 
2
NEUROFARBA, Section of Pharmacology & Toxicology, University of Florence, Viale G. 
Pieraccini 6, 50139, Florence, Italy. 
 
Corresponding author: Paola Failli 
Dept. NEUROFARBA, Section of Pharmacology & Toxicology, Viale G. Pieraccini 6, 50139, 























We demonstrated that in coronary endothelial cells (RCEs) from normotensive Wistar Kyoto rats 
(WKY), the hormone relaxin (RLX) can increase NO production and reduce calcium transient by a 
NO-related mechanism. Since an impairment of the NO pathway has been demonstrated  in the 
spontaneously hypertensive rat (SHR), in the present study we aimed at exploring the effects of 
RLX on RCEs isolated from SHR, hypothesizing that RLX could restore calcium responsiveness to 
NO. 
Experiments were approved by the Animal Subjects Review Board of the University of Florence. 
RCEs were isolated from WKY and SHR. Calcium transient was evaluated by image analysis after 
the administration of angiotensin II (AT II).  
AT-II (1 µM) caused a prompt rise of [Ca
2+
]i in WKY and SHR RCEs and a rapid decrease with a 
decay time higher in SHR than in WKY. NOS inhibition increased calcium transient in WKY, but 
not in SHR RCEs. Whereas RLX pretreatment (24 h, 60 ng/ml) was ineffective in SHR, it strongly 
reduced calcium transient in WKY in a NOS-dependent way. 
The current study offers evidences that RLX cannot restore NO responsiveness in SHR RCEs and 
suggests an accurate selection of patients eligible for RLX treatment of cardiovascular diseases. 
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In the vascular system, the NITRIC OXIDE (NO) pathway mediates vasorelaxation and platelet 
anti-aggregation and protects from ischemic disorders [1]. NO, physiologically produced by 
different nitric oxide synthase isoforms (eNOS, nNOS and iNOS), can activate soluble guanylyl 
cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP) which in turnactivates the 
cGMP-dependent protein kinase (cGK-I), and modulates ion channels, and phosphodiesterases [2]. 
In this context, convincing evidence exists in the literature that the hormone relaxin (RLX) can 
promote coronary and systemic vasodilatation by increasing NO bioavailability and NOS enzyme 
expression [3], thereby reducing hypertension and protecting the heart against ischemia/reperfusion-
induced injury [4,5]. Thus, administration of recombinant human H2 RLX, or serelaxin, has been 
proposed as a potential therapeutic strategy for hypertension and heart ischemia [6]. 
The spontaneously hypertensive rat is an animal model widely used for the study of hypertension, 
hypertensive heart disease and cardiac hypertrophy. In this model, alterations in Ca
2+
 handling have 
been described at very early stages of the disease, even before the appearance of HF [7]. Many 
different factors have been found to be involved in this spontaneous, age-dependent pathological 
condition, including an impairment of the NO pathway. In particular: i) mRNA expression of 
cGMP-dependent protein kinase I (cGKI) was found reduced in aortic rings of 6 week-old SHR [8]; 
ii) decreased cGK activity was detected in ventricular and atrial tissue of aged SHR [9] and other 
forms of hypertensive animals [10] and iii) cGKI expression is reduced in cardiomyocytes and 
coronary endothelial cells (RCEs) of 12 week-old SHR and according to our research data, the 
cGKI expression is reduced in cardiomyocytes and coronary endothelial cells (RCEs) of 12 week 
old SHR [11, 12]. Of note, cGKI is a major regulator of intracellular calcium homeostasis and its 
induced over-expression was found to restore NO-mediated calcium regulation in aortic smooth 
muscle cells and coronary endothelial cells (RCEs) isolated from SHR [13] and RCEs [12].  
Along this line of thought, administration of RLX to SHR was reported to cause a sustained 
decrease in blood pressure and to substantially blunt the vascular response to vasoconstrictors [14, 
15]. Besides these acute functional effects, RLX was also capable of reverting arterial adverse 
remodeling and decreased compliance in elderly SHR [16]. 
The cellular mechanisms underlying these vascular effects of RLX are not fully understood but 
represent matter of investigation because of their obvious medical interest. In this context, previous 
studies performed by our team on RCEs from normotensive Wistar Kyoto (WKY) rats, the normal 
counterpart of SHR, have demonstrated that RLX could increase NO production by up-regulating 
NOS expression and decrease vasoconstrictor-induced [Ca
2+
]i rise by a NO-related mechanism [17]. 
Therefore, it was reasonable to assume that a similar mechanisms may also be operating in SHR.  
In the present study we aimed at exploring the effects of RLX on RCEs isolated from SHR, based 
on the working hypothesis that RLX may restore [Ca
2+
]i responsiveness to NO. According to our 
previous study on normotensive rats, we used angiotensin II (AT-II) to induce [Ca
2+
]i increase in 
RCEs, since these cells have been shown to express AT-II receptors and to respond to exogenous 
AT-II by modulation of NO-dependent [Ca
2+
]i increase [12,18]. Preliminary data were presented at 





: control conditions - At baseline, [Ca
2+
]i, evaluated by Fura 2 fluorescence, was 
112.5±2.76 nM in RCEs isolated from WKY and slightly higher in those from SHR (144.1±7.43 
nM). Stimulation of RCEs with 1 µM AT-II, caused a prompt rise of [Ca
2+
]i in both WKY and SHR 
strains (Fig. 1).  
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Figure 1. Evaluation of [Ca2+]i. in RCE isolated from WKY and SHR rats A) Representative tracings of [Ca2+]i-
associated fluorescence in Fura-2 RCEs from WKY rats in control and RLX-treated cultures upon challenge with AT-II. 
B) Representative tracings of [Ca2+]i-associated fluorescence in Fura 2-loaded RCEs from SHR in control and RLX-
treated cultures upon challenge with AT-II. AT-II (1 μM) was added at the arrow (time = 0) and maintained throughout 
the experiment, as indicated. Cells were incubated for 24 h in serum-free medium in the absence (controls) or presence 
of 60 ng/ml RLX. 
 
 
In the SHR-derived cells, the maximum [Ca
2+
]i increase was slightly, albeit not significantly higher 
than in those from WKY (Fig. 2 A). Calcium signal decreased rapidly in WKY-derived RCEs with 
a decay time of 19.2±0.61 s, whereas in SHR-derived cells, the decay time was significantly higher 
(Fig. 2B). A 10-min. incubation with the NO-donor SNAP significantly decreased maximum 
[Ca
2+
]i increase and decay time in the WKY-derived cells, whereas it was ineffective in the SHR-
derived ones (Fig. 2). Moreover, 20-min. preincubation with the non-selective NOS inhibitor L-
NAME significantly increased maximum [Ca
2+
]i increase and decay time in the WKY-derived, but 
not in the SHR-derived cells. Inhibition of NOS II with W1400 had no effect on calcium transient in 
both strains.  
 



























































Figure 2. Evaluation of [Ca
2+
]i in RCE isolated from WKY and SHR rats. [Ca
2+
]i increase (peak, A) and [Ca
2+
]i 
transient decay time (B) in WKY- and SHR-derived RCEs. SNAP (100 µM), L-NAME (10 µM) or W1400 (1 µM) 
were incubated 20 min before the administration of AT-II (1 µM). Values are the mean (± S.E.M.) of data from three 
separate RCE cell isolations, where at least 20-24 cells for each type of protocols were analyzed separately. Segments 
on the top of bars indicate significance between WKY and SHR; stars indicate significance between treatment and 





]: RLX effects - In WKY-derived RCEs, a 24-h incubation with RLX decreased 
both peak and decay time of the agonist-induced [Ca
2+
]i transient (Fig. 1A, Fig. 3): the effect of 
RLX preincubation was potentiated by a 10-min. incubation with SNAP. A 20-min. incubation with 
either the nonspecific NOS inhibitor L-NAME or the selective NOS II inhibitor 1400W modified 
the kinetic of AT-II induced [Ca
2+
]i transient in RLX-treated WKY-derived RCEs: as shown, both 
inhibitors were able to increase the maximum and the decay time of the calcium transient. A similar 
24h incubation with RLX in SHR-derived cells was ineffective in reducing the calcium transient, as 
evaluated by maximum and decay time. Again, in SHR-derived cells, the short incubation with 
SNAP or with both NOS inhibitors did not modify calcium transient in the RLX-pretreated cells. 
 













































Figure 3. Evaluation of [Ca
2+
]i in RCE isolated from WKY and SHR rats pretreated with RLX. [Ca
2+
]i increase 
(peak, A) and [Ca
2+
]i transient decay time (B) in WKY- and SHR-derived RCEs. Cells were pretreated with RLX (60 
ng/ml) for 24 h; SNAP (100 µM), L-NAME (10 µM) or W1400 (1 µM) were incubated 20 min. before the 
administration of AT-II (1 µM). Values are the mean (± S.E.M.) of data from three separate RCE cell isolations, where 
at least 20-24 cells for each type of protocols were analyzed separately. Segments on the top of bars indicate 
significance between WKY and SHR; stars indicate significance between treatment and control, same strain: ***P < 




The present data confirm that [Ca
2+
]i in RCEs isolated from normotensive WKY rats is strongly 
modulated by the NO pathway. In particular, while a NO donor decreases the calcium transient 
induced by AT-II, an aspecific inhibitor of NOS (L-NAME) can increase it. Moreover, the hormone 
RLX, known for its vasodilatory properties [5], also reduces calcium transient: this effect appear to 
be related to NOS II induction and enhanced endogenous NO generation [17], as can be judged by 
the effectiveness of the NOS II inhibitor W1400, which is ineffective in the control cells not treated 
with RLX. These data confirm the important role of NO in endothelial cells as modulator of 
calcium signal in physiologically normal rats and suggest that NO can act in an autocrine manner 
[17]. A remarkably different behavior is observed in SHR-derived RCEs. In fact, in these cells, NO 
is unable to modulate [Ca
2+
]i and this ineffectiveness is maintained after treatment with RLX, 
suggesting that a downstream step of the NO pathway is altered. In this context, we have previously 
reported that SHR-derived RCEs show low/absent expression of cGKI enzyme [12]. Moreover, a 
similar reduction of cGKI has been described in cardiomyocytes  [11] and aortic smooth muscle 
cells [13]. The present data that RLX is unable to restore NO responsiveness in SHR-derived RCEs 
appears to be at variance with previous in vivo studies in which RLX reduced blood pressure when 
administered to SHR [14]. This discrepancy may depend on many reasons, including that, in vivo, 
RLX could directly exert its effects on vascular smooth muscle cells, whose contractility is 
inhibited by RLX [24]. Of note, a direct NO-mediated relaxant effect of RLX on smooth 
musculature has been consistently described in other target organs, including the uterus [25,26] and 
the gastrointestinal tract [27]. 
The current study, while offering additional evidences that RLX cannot restore NO responsiveness 
in SHR-derived RCEs, further underlines the importance of the NO/sGK/cGKI pathway in 
controlling the [Ca
2
]i dynamics presiding to the regulation of vascular tone. This notion may have 
clinical implications, as it suggests that caution is required in identifying the cohort of patients that 
may be successfully treated with NO-modulating drugs for cardiovascular diseases. A genome-wide 
association study found that the common genetic variants in human cGKI-1 gene (PRKG1) are 
significantly associated with changes in diastolic blood pressure in response to an acute salt load in 
patients with hypertension [28]. Chronically elevated blood pressure increases left ventricular (LV) 
load, enhances LV radial systolic performance and leads to LV hypertrophy. Recently, LV systolic 
radial function has been associated with common polymorphisms in PRKG1 [29]. In particular, LV 
radial systolic deformation (strain) is significantly higher in GAT homozygotes of PRKG1gene than 
in heterozygotes and noncarriers. Even if further studies must be undertaken to elucidate how the 
genetic variants of PRKG1 might influence cardiovascular diseases, these data suggest that NO-
enhancing drugs and RLX  in these patients could negatively influence the correct clinical 
evaluation of their actual efficacy in the treatment of hypertension and hypertensive heart diseases. 
 
 
Materials and Methods 
Chemicals 
Highly purified porcine RLX (2,500-3,000 U/mg) was the generous gift of O. D. Sherwood. RLX 
was used at a concentration of 60 ng/ml, which is in the range of that found effective in inducing 
coronary vasodilatation in rat hearts [20]. Media, sera, and reagents for cell culture were from 
Sigma-Aldrich (Milan, Italy) and Gibco Life Technologies (Milan, Italy). Cell culture plastic ware 
was purchased from Costar (Corning Costar Co., Costar Italia, Milan, Italy). Fura 2-AM and 
Pluronic F127 were from Molecular Probes Life Technologies (Milan, Italy). The selective NOS II 
inhibitor 1400W [21] was from Alexis Biochemicals (Enzo Life Sciences, New York, U.S.A.) and 
the NO-donor S-nitroso-N-acetylpennicillamine (SNAP) from Tocris (Bristol, U.K.). NG-nitro-L-
arginine methylester (L-NAME) and angiotensin II (AT II) were from from Sigma-Aldrich (Milan, 
Italy) as were the other chemicals used. 
 
Isolation and culture of rat coronary endothelial (RCE) cells 
RCEs were isolated from the heart of 3-4-month old male Wistar Kyoto and aged matched SHR 
rats, as described previously [22]. Rats (Charles River, Lecco, Italy) were housed in the Centro per 
la Stabulazione degli Animali da Laboratorio (Ce.S.A.L., University of Florence), maintained for at 
least one week after their arrival in a 12 hours dark-light cycle with pellet food and water ad 
libitum. Formal approval to conduct the experiments described was obtained from the Animal 
Subjects Review Board of the University of Florence. The ethics policy of the University of 
Florence complies with the Guide for the Care and Use of Laboratory Animals of the U.S. National 
Institutes of Health (NIH Publication No. 85-23, revised 1996; University of Florence Assurance 
No. A5278-01).  
Briefly, after enzymatic digestion of the heart, the suspension was centrifuged and the pellet was 
stirred for 30 min at 37°C in the presence of 10 mg/50 ml trypsin. The recovered pellet was 
resuspended in 15 ml of culture medium (see below), and plated. After 4 h, cells were washed twice 
and grown until confluence (5-6 days) in M199 containing 10% fetal calf serum (FCS), 10% 
newborn calf serum, 250 U/ml penicillin G, 0.625 µg/ml amphotericin, and 250 µg/ml 
streptomycin. Isolated RCEs were cytocharacterized as previously reported [22,23]. Cells 
immunoreactive for endothelial markers ranged between 96% and 98%. For all experiments, cells 
were used at the first passage. Stimulation of RCEs with RLX was carried out in M199 medium 
without phenol red. 
Determination of intracellular Ca
2+




]i) was evaluated with Fura-2 
by microscopic image analysis as described previously [12,22]. Briefly, cells were grown on round 
cover slips to subconfluence and then incubated for 24 h in serum-free medium in the absence 
(controls) or presence of RLX (60 ng/ml). Cells were loaded with the Ca
2+
-sensitive fluorescent 
probe Fura 2-AM (4 µmol/l) and Pluronic F (0.02%) for 45 min at room temperature in HEPES-
bicarbonate buffer containing (mM): NaCl 140, KCl 2.9, NaH2PO4 0.5, NaHCO3 12, MgCl2 0.9, 
HEPES 10, CaCl2 1, glucose 10, adjusting pH to 7.4 with NaOH 1 N. 
Coverslips were washed and mounted in the stage of an epifluorescence inverted microscopy in a 
perfusion chamber warmed at 35°C.  [Ca
2+
]i was measured dynamically by monitoring Fura-2 
fluorescence ratio. Consecutive images, obtained with excitation wavelengths of 340 and 380 nm 
and an emission wavelength of 510 nm, were recorded with a charge coupled device (CCD) video 
camera and digitized by an analogical/digital converter (resolution: 256×256 pixels, time interval 
between subsequent images: 800 ms). Image ratios (340/380 nm) were obtained every 3 s on a 
pixel-to-pixel basis after subtraction of the background.  
After measurements of [Ca
2+
]i in basal conditions, 1µM AT II was added directly into the perfusion 
chamber, and the time course of [Ca
2+
]i increase induced by the agonist was analyzed for at least 15 
min as already described [12,22]. A noise/signal ratio of 0.5 of 340/380 nm fluorescence was 
considered as the lowest detectable limit for [Ca
2+
]i transient.  In some experiments, 100 M 
SNAP, the broad-spectrum NOS inhibitor L-NAME (10 µM) or the specific NOS II inhibitor 
1400W (1 µM) were added to the perfusion chamber 20 min before the addition of the agonist. 
Calibration curves were performed using a Kd of 214 nM for Fura-2. 
The experimental data were exported as ASCII file format and graphically elaborated with 
MicroCal Origin 9 software (OriginLab, Northhampton, MA). The decay time of calcium transient 
was calculated as reported previously [22] and expressed as the time (s) needed for fluorescence 
ratio to reach 36.79% of the maximal value. The reported values are the mean (± SE) of data from 
three separate RCE cell isolations, where at least 20-24 cells for each type of protocols were 
analyzed separately. 
 
Calculations and statistical analysis 
Statistical comparisons were performed by using one-way ANOVA test followed by Student-
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